Abstract
Noninvasive biomarkers for immune checkpoint inhibitors remain a compelling unmet medical need. POLARIS-03 is a multicenter phase II trial to evaluate the safety and efficacy of toripalimab (anti-PD-1) in refractory metastatic urothelial carcinoma (mUC). We assessed the predictive utility of longitudinal circulating tumor DNA (ctDNA) analysis from a single-institution biomarker cohort.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have